Drug Database · Clinicians

Flunarizine

Brands (2) Flumig, FlunizShow all

Antimigraine; Antivertigo PH FDA category

Rx · Prescription drug2 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • History of depression
  • Parkinson disease or other extrapyramidal disorders
  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Migraine prophylaxis (adults under 65): 10 mg once daily in the evening; stop if no improvement after 3 months
renalcarematters.com, reviewed

Dosing: Altered kidney function

Flunarizine is highly protein-bound (over 99%), metabolized by the liver and excreted very slowly, with negligible urinary excretion; its terminal half-life is about 19 days. The Canadian product monograph does not address kidney impairment or dialysis. It has no US FDA label.

Kidney function measure: The product monograph does not address kidney impairment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Migraine prophylaxis: 10 mg once daily in the evening (adults under 65); stop after 3 months if no response (PM).
CrCl 30–59 mL/min
The product monograph does not address kidney impairment. Renal excretion is negligible (under 0.2% in urine over 48 hours). Use with caution and specialist judgment.
CrCl 15–29 mL/min
The product monograph does not address kidney impairment. Renal excretion is negligible (under 0.2% in urine over 48 hours). Use with caution and specialist judgment.
CrCl <15 mL/min (not on dialysis)
The product monograph does not address kidney impairment. Renal excretion is negligible (under 0.2% in urine over 48 hours). Use with caution and specialist judgment.
Hemodialysis (intermittent)
Not studied in dialysis; no dose given.
Peritoneal dialysis
Not studied in dialysis; no dose given.
CRRT
Not studied in dialysis; no dose given.
  • Dialyzable? Not stated (over 99% protein-bound; removal unlikely).
  • Monitoring Depression (contraindicated with a history of depression), extrapyramidal symptoms (higher risk in older adults), sedation, weight gain; stop at the first sign. Review at 3 months and closely beyond 6 months (PM). Caution in hepatic impairment (PM); safety above 65 years not established.
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: Health Canada product information (February 15, 2022). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not established under 18 years (PM).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Capsule: 5 mg

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Flunarizine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Flunarizine
Package insert
FlumigFlunarizine Hydrochloride
5 mg capsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Unison Laboratories Co., Ltd.Thailand
JustRight Healthcare Inc.
DR-XY31562
Dec 18, 2028
FlunizFlunarizine (as dihydrochloride)
5 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Ravian Life Science Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-14967
Feb 27, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Alcohol, hypnotics, tranquilizersAvoidExcessive sedation.Avoid.
AntihypertensivesAdjust or monitorAdditive blood-pressure lowering.Antihypertensive dose may need reduction.
Two or more enzyme-inducing antiepileptics; mephenytoinMinorLower flunarizine levels.Monitor response.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Somnolence, sedation or fatigue (about 20%)
  • Weight gain or increased appetite (about 15%)

Serious

  • Depression
  • Extrapyramidal symptoms, parkinsonism
  • Galactorrhea
renalcarematters.com, reviewed

Monitoring parameters

  • Depression (contraindicated with a history of depression), extrapyramidal symptoms (higher risk in older adults), sedation, weight gain; stop at the first sign. Review at 3 months and closely beyond 6 months (PM). Caution in hepatic impairment (PM); safety above 65 years not established. Kidney
  • Mood; extrapyramidal signs; review at 3 and 6 months
  • Caution in hepatic impairment; safety over 65 years not established
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peak2 to 4 hours
Half-lifeAbout 19 days (terminal)
Volume of distribution43.2 L/kg (mean)
Protein binding99.1% (under 1% free)
Metabolism (CYP, transporters)Hepatic N-oxidation and aromatic hydroxylation
Renal excretion kidneyUnder 0.2% in urine over 48 hours
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Flunarizine (as hydrochloride)
PNF listingOral: 5 mg capsule
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Canada. Flunarizine capsules product monograph (AA Pharma) [Health Canada product information, February 15, 2022; no US FDA label]. https://pdf.hres.ca/dpd_pm/00065007.PDF
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. AA Pharma Inc. (2022). Flunarizine (flunarizine hydrochloride) capsules 5 mg [Product monograph; revised February 15, 2022]. Health Canada Drug Product Database. https://pdf.hres.ca/dpd_pm/00065007.PDF

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .